Arcutis Biotherapeutics
ARQT
78 hedge funds and large institutions have $1.15B invested in Arcutis Biotherapeutics in 2020 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 33 increasing their positions, 12 reducing their positions, and 8 closing their positions.
200% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 8
175% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 12
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
24% more funds holding
Funds holding: 63 → 78 (+15)
13% more capital invested
Capital invested by funds: $1.02B → $1.15B (+$135M)
2.88% more ownership
Funds ownership: 91.03% → 93.91% (+2.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$34.3M |
| 2 |
BlackRock
New York
|
+$20.5M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$20.4M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$20M |
| 5 |
State Street
Boston,
Massachusetts
|
+$14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$17.8M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$6.03M |
| 3 |
Ameriprise
Minneapolis,
Minnesota
|
-$4.15M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$1.47M |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
-$696K |
ARQT Hedge Fund Activity: Q4 2020 in Review
78 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q4 2020, worth a combined $1.15B — up 13% from $1.02B a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new ARQT positions and 8 closed out — a net gain of 16 holders — while 33 added to existing stakes and 12 trimmed.
The largest buyer was OrbiMed, adding an estimated $34.3M. The largest seller was T. Rowe Price Associates, cutting an estimated $17.8M.
- 78 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q4 2020, up from 63 in Q3 2020.
- Funds reported $1.15B of Arcutis Biotherapeutics stock for Q4 2020, up 13% quarter-over-quarter.
- 24 funds opened new Arcutis Biotherapeutics positions in Q4 2020 and 8 closed out, a net change of +16 holders.
- The largest Arcutis Biotherapeutics buyer in Q4 2020 was OrbiMed, an estimated $34.3M added.
- The largest Arcutis Biotherapeutics seller in Q4 2020 was T. Rowe Price Associates, an estimated $17.8M sold.
Based on aggregated 13F filings for Q4 2020.